Dua Anisha B, Kalot Mohamad A, Husainat Nedaa M, Byram Kevin, Springer Jason M, James Karen E, Chang Lin Yih, Turgunbaev Marat, Villa-Forte Alexandra, Abril Andy, Langford Carol, Maz Mehrdad, Chung Sharon A, Mustafa Reem A
Northwestern University Feinberg School of Medicine, Chicago, Illinois.
State University of New York at Buffalo.
ACR Open Rheumatol. 2021 Feb;3(2):80-90. doi: 10.1002/acr2.11186. Epub 2021 Jan 29.
Takayasu's arteritis (TAK) is a granulomatous large-vessel vasculitis primarily affecting the aorta and its proximal branches. TAK can be a difficult disease to diagnose and manage given the rarity of the disease as well as current limitations in biomarkers, imperfect imaging modalities, and few randomized controlled trials.
In developing the American College of Rheumatology/Vasculitis Foundation guideline for the management of TAK, we performed an extensive systematic literature review to guide our recommendations. We included RCTs first. When RCTs were not available, we included observational studies that reported on patient-important outcomes for the intervention and comparison. When studies with comparative data were not available, we included case series that present patient-important outcomes for either the intervention or the comparison.
Three hundred forty-seven articles were included for full review to answer 27 population, intervention, comparison, and outcome questions related to TAK. Ten studies were evaluated that addressed the use of glucocorticoids (GCs), non-GC nonbiologic therapies, as well as biologics in treating TAK. A total of 33 studies, including 8 comparative studies, were included to determine the test accuracy of commonly available diagnostic tests for TAK.
This comprehensive systematic review synthesizes and evaluates the benefits and harms of different treatment options and the accuracy of commonly used tests for the management of TAK.
高安动脉炎(TAK)是一种肉芽肿性大血管血管炎,主要累及主动脉及其近端分支。鉴于该疾病的罕见性以及生物标志物方面的当前局限性、成像方式不完善和随机对照试验较少,TAK可能是一种难以诊断和管理的疾病。
在制定美国风湿病学会/血管炎基金会TAK管理指南时,我们进行了广泛的系统文献综述以指导我们的建议。我们首先纳入随机对照试验。当没有随机对照试验时,我们纳入报告了干预措施和对照的对患者重要结局的观察性研究。当没有具有比较数据的研究时,我们纳入呈现干预措施或对照的对患者重要结局的病例系列。
共纳入347篇文章进行全面审查,以回答与TAK相关的27个关于人群、干预措施、对照和结局的问题。对10项研究进行了评估,这些研究涉及糖皮质激素(GCs)、非GC非生物疗法以及生物制剂在TAK治疗中的应用。总共纳入33项研究,包括8项比较研究,以确定TAK常用诊断测试的测试准确性。
这项全面的系统综述综合并评估了不同治疗方案的益处和危害以及TAK管理中常用测试的准确性。